TUCSON, Ariz., April 14, 2015 /PRNewswire/ -- On April 9, SynCardia Systems, Inc. was honored with the 2015 Medical Company of the Year Award in the 8th annual Az Business magazine Healthcare Leadership Awards.
"The Healthcare Leadership Awards honors the women, men and institutions whose passion and innovation are saving lives, extending lives and improving the quality of our lives," says Cheryl Green, publisher for AZ Big Media, which publishes Az Business magazine, Arizona's largest business publication.
A panel of industry experts named finalists and award winners in 11 healthcare categories. SynCardia was one of three finalists in its category with the other finalists being Medtronic and Insys Therapeutics.
"Tucson and Arizona is the international headquarters for the first and only FDA, Health Canada and CE-mark approved Total Artificial Heart in the world," says Michael P. Garippa, CEO and President of SynCardia. "From 1969 through 2014 there have been 1,458 implants of 13 different artificial heart designs. The SynCardia Total Artificial Heart and its direct predecessors account for 1,397 or 96% of all implants."
Similar to a donor heart transplant, the SynCardia Total Artificial Heart is the only approved device that eliminates the source of end-stage biventricular heart failure in which the native heart's two ventricles can no longer pump enough blood for a person to survive.
In the United States, the SynCardia Total Artificial Heart is approved as a bridge to donor heart transplant. In Europe, the 70cc and 50cc SynCardia Hearts are used as a bridge to a donor heart transplant and for destination therapy, also known as permanent use. Use of SynCardia Hearts for destination therapy varies by country.
SynCardia is conducting an FDA-approved clinical study on the effectiveness of the SynCardia Total Artificial Heart for use as destination therapy in the United States. (CAUTION-The 70cc SynCardia Total Artificial Heart, when used for destination therapy, is an investigational device, limited by United States law to investigational use.)
SynCardia also has begun an FDA-approved clinical study for the use of its smaller, 50cc version of the SynCardia Total Artificial Heart as a bridge to donor heart transplant. Its size is intended for use by women, smaller men and many adolescents. (CAUTION-In the United States, the 50cc SynCardia temporary Total Artificial Heart is an investigational device, limited by United States law to investigational use.)
For additional information, please visit: http://www.syncardia.com/
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn
Share and Discover on Google+
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. in Tucson, Arizona is the manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,400 implants of the SynCardia Total Artificial Heart account for over 400 patient years of life on the device. Since January 2010 more than 600 SynCardia Hearts have been implanted.
The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 80 years old. The longest a patient has lived with a SynCardia Heart was nearly four years (1,374 days) before receiving a successful donor heart transplant.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital and live at home and in their communities. The Freedom driver has been used by more than 200 patients, accounting for over 130 patient years of support.
SOURCE SynCardia Systems, Inc.